| Ningbo Kilo Biotechnology Co., Ltd. | China | |||
|---|---|---|---|---|
![]() | www.kilobio.com | |||
![]() | +8613989352104 | |||
![]() | terry.zhang@kilobio.com | |||
![]() | QQ Chat | |||
![]() | WeChat: Wenzhou Medical University | |||
| Chemical distributor since 2023 | ||||
| chemBlink Standard supplier since 2023 | ||||
| Classification | Biochemical >> Amino acids and their derivatives |
|---|---|
| Name | Epitalon |
| Synonyms | (4S)-4-[[(2S)-2-aminopropanoyl]amino]-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| Molecular Structure | ![]() |
| Molecular Formula | C14H22N4O9 |
| Molecular Weight | 390.35 |
| Protein Sequence | AEDG |
| CAS Registry Number | 64082-79-7 |
| SMILES | C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N |
|
Epitalon is a defined tetrapeptide made up of alanine, glutamate, aspartate, and glycine. Its short sequence distinguishes it from mixtures of peptides extracted from tissues. The distinction is crucial when interpreting reports about biological effects: an observation about a mixture cannot establish what one purified four-residue sequence does. The best-known experimental question concerns telomeres, the DNA-protein structures at chromosome ends. In dividing cells, telomere length can change over successive rounds of replication. Telomerase can add repeats at chromosome ends. In an experiment summarized in FDA advisory materials, investigators reported changes in telomerase activity and telomere length in cultured human fibroblasts exposed to epitalon. These measurements are informative about the cells and culture conditions used. There is a long distance between a chromosome-end measurement and evidence about human aging. Cells grown in a dish lack the interacting organs, immune system, and pharmacokinetics of a person. Telomere length is also not a comprehensive measure of health. Some cells maintain telomeres in circumstances where continued proliferation is not beneficial. Thus a longer telomere in a cell model cannot be treated as evidence of longer life, improved function, or reduced disease risk in people. The sequence also helps define what analytical testing would need to establish. The same four types of amino acids can be connected in different orders, and measuring overall composition does not resolve the order of the residues. A result attributed to a specific peptide depends on identifying that peptide rather than merely demonstrating that its constituent amino acids are present. This is a separate issue from assessing biological activity. The FDA advisory discussion also highlights a separate question: a peptide's identity on paper does not establish the quality or safety of a preparation. Aggregation and peptide-related impurities can affect the evaluation of compounded products. These are distinct from whether an experiment supports an effect on telomerase. Epitalon's case offers a useful lesson in evidence: a defined structure, a measurable cellular response, and a demonstrated human benefit are three separate steps. References: 1. FDA Pharmacy Compounding Advisory Committee briefing, epitalon evidence review. https://www.fda.gov/media/193774/download 2. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks |
| Market Analysis Reports |